



## **NervGen Pharma Announces Results of Annual General Meeting of Shareholders**

- All resolutions submitted for approval were passed by shareholders

**Vancouver, Canada, May 7, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF)**, a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 6, 2025.

The company reports that at the AGM the shareholders re-elected Brian Bayley, Harold Punnett, Randall Kaye, Krista McKerracher, Glenn Ives, Craig Thompson, Adam Rogers, John Ruffolo, Neil Klompas and Michael Kelly to serve in office until the next annual meeting or until their successors are duly elected or appointed. The shareholders also voted in favour of the re-appointment of KPMG LLP, Chartered Accountants, as auditors of the company until the next annual meeting of the company's shareholders or until their successors are duly appointed. In addition, the shareholders approved by disinterested shareholder vote, certain amendments to the company's existing stock option plan, including an increase in the number of shares reserved for issuance.

### **About NervGen**

NervGen (TSXV: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new discovery lead, NVG-300, in models of ischemic stroke and spinal cord injury. For more information, visit [www.nervgen.com](http://www.nervgen.com) and follow NervGen on [X](#), [LinkedIn](#), and [Facebook](#) for the latest news on the company.

### **About NVG-291**

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology was licensed from Case Western Reserve University and is based on academic studies demonstrating the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in preclinical models of spinal cord injury. Effects of NVG-291-R reported in multiple independent academic studies include the promotion of neuroplasticity, remyelination, anti-inflammatory polarization of microglia, and functional improvement in preclinical models of spinal cord injury, stroke, dementia, and peripheral nervous system injury. NVG-291 has received Fast Track designation in spinal cord injury from the FDA.

### **Contacts**

Huitt Tracey, Investor Relations  
[htracey@nervgen.com](mailto:htracey@nervgen.com)  
604.537.2094

Bill Adams, Chief Financial Officer  
[info@nervgen.com](mailto:info@nervgen.com)  
778.731.1711

Christy Curran  
Sam Brown Healthcare Communications  
[christycurran@sambrown.com](mailto:christycurran@sambrown.com)  
615.414.8668  
646.942.5604

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

#### **Cautionary Note Regarding Forward-Looking Statements**

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation (collectively, “forward-looking statements”). Such forward-looking statements herein include but are not limited to, the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “trend”, “indication”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the objectives and timing, of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the development plans and timelines for NVG-300; and the creation of neurorestorative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease.

Forward-looking statements are based on estimates and assumptions made by the company in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions.

Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the “Risk Factors” section of the company’s most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca). All clinical development plans are subject to additional funding.

Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events

or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.